Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Grade 3b Follicular Lymphoma: early-phase trial registry

4 of 5 indexed Grade 3b Follicular Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Grade 3b Follicular Lymphoma: 5 US clinical trials tracked, 4 recruiting.

Grade 3b Follicular Lymphoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is SWOG Cancer Research Network, running 2 of these trials.

Enrollment posture brief

Registry condition grade-3b-follicular-lymphoma

OPEN 4 | RECR 80% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Grade 3b Follicular Lymp (th…80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Grade 3b Follicular Lymphoma

Grade 3b Follicular Lymphoma lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Grade 3b Follicular Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Grade 3b Follicular Lymphoma is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Grade 3b Follicular Lymphoma research.

    SWOG Cancer Research Network accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Grade 3b Follicular Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 52 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Grade 3b Follicular Lymphoma research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Named interventions

Most-linked intervention names on Grade 3b Follicular Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
3 trials
Computed Tomography Procedure
2 trials
Biospecimen Collection Procedure
2 trials
Fludarabine Drug
2 trials
Retifanlimab Biological
1 trials
Axicabtagene Ciloleucel Biological
1 trials
Vorinostat Drug
1 trials
CD79b-19 CAR T cells Drug
1 trials

US sites by state

Facility locations filed on Grade 3b Follicular Lymphoma trials. A trial with sites in several states counts in each.

California 3 trials
Illinois 2 trials
Florida 2 trials
Arizona 2 trials
Washington 1 trials
Massachusetts 1 trials
Idaho 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Grade 3b Follicular Lymphoma page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Grade 3b Follicular Lymphoma condition card totals 5 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.